ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1390

One-year Real World Evidence Outcomes from the Cohort RADIUS (Real-world Analysis of Upadacitinib in Rheumatoid Arthritis Patients for Improved Understanding and Safety)

Luis Gomez-Lechon Quiros1, José Miguel Sequí-Sabater2, Amalia Rueda3, Costas Torrijo Nerea4, Carlos Valera-Ribera5, Juan Miguel López-Gómez6 and Antonio Alvarez-Cienfuegos7, 1Hospital Francesc de Borja, Valéncia, Spain, 2La Ribera University Hospital, Rheumatology Department, Gandía, Comunidad Valenciana, Spain, 3Hospital General de Valencia, VALENCIA, Comunidad Valenciana, Spain, 4Generalitat valenciana, Valencia, Spain, 5Hospital Doctor Peset, Valéncia, Comunidad Valenciana, Spain, 6Conselleria de Sanitat/Hospital Universitario de Elda, Elda, Comunidad Valenciana, Spain, 7Conselleria de Sanitat/Hospital de la Vega Baja, Orihuela, Comunidad Valenciana, Spain

Meeting: ACR Convergence 2024

Keywords: Cohort Study, Disease Activity, Health Care, rheumatoid arthritis, risk factors

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: RA – Treatment Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Rheumatoid Arthritis (RA) is a chronic inflammatory disease that affects the joints and other parts of the musculoskeletal system. Early diagnosis and initiation of treatment are essential for patients with RA given the potentially irreversible damage to the joints and the considerable impact on quality of life.

Upadacitinib is an oral reversible JAK inhibitor with greater selectivity for JAK1 over JAK2, JAK3 and TYK2, which has been approved for the treatment of moderately to severely active RA in adult patients with inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs). Despite its extensive clinical development in RA, few studies with a significant number of patients reflect efficacy and safety data of the drug in real clinical practice.
We aim to evaluate the efficacy (DAS28-CRP) and safety of upadacitinib in treating RA in routine clinical practice.

Methods: This is a multicenter, observational and retrospective study that includes the use of Upadacitinib in real clinical practice. To this end, 202 patients diagnosed with RA according to the EULAR/ACR 2010 criteria are included and followed up for up to 52 weeks. Five visits were carried out (baseline, 3 months, 6 months, 9 months and 12 months) although when collecting data according to clinical practice, the data analysis was registered as observed. In addition to disease activity data, comorbidity, previous treatments, use of Upadacitinib in monotherapy, use of corticosteroids and previous or incident HZV infection are collected. Association and correlation studies were performed using SPSS v.25.

Results: 202 patients were included, of whom 148 were women, with a mean age of 56.52 years. The rest of baseline characteristics are reflected in Table 1. In 32.18% of patients, upadacitinib was used in monotherapy, while in the rest of the patients, its use was combined with csDMARDs, mostly with methotrexate (87.63%). We found not statistical differences between patients who started with monotherapy or had previous bDMARDs regarding drug interrumption (p >0,05).

Three months after starting treatment, 32.64% (63) of the patients were in remission while 19.69% (38) were in low, 41.97% (81) moderate and 5.7% (11) in high activity. At 6 months after starting treatment, 45.68% (74) of the patients were in remission while 25.3% (41) were in low, 24.07% (39) in moderate and 4.94% (8) in high activity. At 12 months after starting treatment, of the patients who continued with treatment or for whom a recorded visit was available, 77.2% (105) of patients were in remission while 11.02% (15) were in low, 11.76% (16) in moderate and none in high activity.

Treatment was suspended in 32.67% (66) of the patients, of which 33.3% (22) were due to primary failure, 34.85% due to secondary failure, 15.15% (10) due to adverse effect, 13.63% (9) due to the patient’s request and 3.03% (2) for other reason.

Conclusion: Concording with literature this study demonstrates the drug’s effectiveness, reaching more than half of the sample at the end of the year with low activity or complete remission, and presenting expected side effects. There are no differences in starting with monotherapy or combined bDMARDs regarding drug interrumption.

Supporting image 1

Table 1. Baseline characteristics

Supporting image 2

Table 2. Change in DAS28-CRP activity levels over the period of one year

Supporting image 3

Figure 1. Evolution in time of the cohort’s DAS28-CRP activity


Disclosures: L. Gomez-Lechon Quiros: None; J. Sequí-Sabater: None; A. Rueda: None; C. Nerea: None; C. Valera-Ribera: None; J. López-Gómez: None; A. Alvarez-Cienfuegos: None.

To cite this abstract in AMA style:

Gomez-Lechon Quiros L, Sequí-Sabater J, Rueda A, Nerea C, Valera-Ribera C, López-Gómez J, Alvarez-Cienfuegos A. One-year Real World Evidence Outcomes from the Cohort RADIUS (Real-world Analysis of Upadacitinib in Rheumatoid Arthritis Patients for Improved Understanding and Safety) [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/one-year-real-world-evidence-outcomes-from-the-cohort-radius-real-world-analysis-of-upadacitinib-in-rheumatoid-arthritis-patients-for-improved-understanding-and-safety/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/one-year-real-world-evidence-outcomes-from-the-cohort-radius-real-world-analysis-of-upadacitinib-in-rheumatoid-arthritis-patients-for-improved-understanding-and-safety/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology